Docteur MARIE KOSTINE
✨ Profil synthétique
IA · 30/04/2026Le Docteur Marie Kostine est un rhumatologue hospitalier à Le Bouscat, avec une activité de recherche significative dans le domaine de la rhumatologie et de l'oncologie. Son h-index élevé de 31 et ses 133 publications démontrent son engagement dans la recherche académique. Ses travaux de recherche couvrent notamment la polyarthrite rhumatoïde, les biomarqueurs et les thérapies contre le cancer.
Expertises présumées
- Polyarthrite rhumatoïde
- Biomarqueurs en oncologie
- Thérapies ciblées contre le cancer
- Corticothérapie
- Pharmacovigilance en rhumatologie
- Épidémiologie des maladies rhumatismales
- Recherche sur la leucémie lymphoïde chronique
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.
Diplômes
🎓 DES & spécialité ordinale
- DES Rhumatologie
- Rhumatologie (SM)
🎓 Diplômes
- DE Docteur en médecine
Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.
Thèses universitaires
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Activité de recherche & publications
Source : bases de données publiques (OpenAlex, PubMed).
h-index
31
h articles cités ≥ h fois chacun. Un h de 31 = 31 publications avec 31+ citations.
Citations
5 562
Publications
133
i10-index
46
Thématiques principales
- Cancer Immunotherapy and Biomarkers ×57
- Rheumatoid Arthritis Research and Therapies ×17
- Chronic Lymphocytic Leukemia Research ×14
- Otitis Media and Relapsing Polychondritis ×13
- Colorectal Cancer Treatments and Studies ×11
Affiliations FR : Centre Hospitalier Universitaire de Bordeaux · Hôpital Saint-André · Hôpital Pellegrin
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Bibliographie
Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: A narrative review
2026ArticleJoint Bone Spine
Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome
2025ArticleBlood
Correction: Neurological manifestations in patients with VEXAS syndrome
2025ArticleJournal of Neurology
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial
2025ArticleEuropean Journal of Cancer
Neurological manifestations in patients with VEXAS syndrome
2025ArticleJournal of Neurology
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry
2024ArticleAnnals of the Rheumatic Diseases
Diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease: Data from the French Tw-IRD registry
2024ArticleJournal of Infection
Clinical impact of proton pump inhibitors and other co-medications on advanced melanoma patients treated with BRAF/MEK inhibitors
2024ArticleEuropean Journal of Cancer
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Lieu de consultation
HOPITAL SUBURBAIN DU BOUSCAT
97 Avenue GEORGES CLEMENCEAU, 33491 Le Bouscat
☎ 0556424949Hospitalier
Tarifs & secteur de conventionnement
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Prendre rendez-vous & contact
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Top publications · les plus citées
- 1Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
Arthritis & rheumatology (Hoboken, N.J.) · 2019
Lire l'abstract Crossref ↓
ObjectiveImmune checkpoint inhibitors (ICIs) for cancer therapy frequently induce immune‐related adverse effects (IRAEs). Therefore, most patients with preexisting autoimmune diseases have been excluded from clinical trials of ICIs. This study was undertaken to evaluate the safety and efficacy of ICIs in patients with preexisting autoimmune disease and cancer.MethodsA retrospective cohort study was conducted from January 2017 to January 2018 via 3 French national networks of experts in oncology and autoimmunity. Adults with preexisting autoimmune disease who were receiving ICIs were assessed for the occurrence of flare of preexisting autoimmune disease, other IRAEs, and cancer response.ResultsThe study included 112 patients who were followed up for a median of 8 months. The most frequent preexisting autoimmune diseases were psoriasis (n = 31), rheumatoid arthritis (n = 20), and inflammatory bowel disease (n = 14). Twenty‐four patients (22%) were receiving immunosuppressive therapy at ICI initiation. Autoimmune disease flare and/or other IRAE(s) occurred in 79 patients (71%), including flare of preexisting autoimmune disease in 53 patients (47%) and/or other IRAE(s) in 47 patients (42%), with a need for immunosuppressive therapy in 48 patients (43%) and permanent discontinuation of ICI in 24 patients (21%). The median progression‐free survival was shorter in patients receiving immunosuppressive therapy at ICI initiation (3.8 months versus 12 months; P = 0.006), confirmed by multivariable analysis. The median progression‐free survival was shorter in patients who experienced a flare of preexisting autoimmune disease or other IRAE, with a trend toward better survival in the subgroup without immunosuppressant use or ICI discontinuation.ConclusionOur findings indicate that flares or IRAEs occur frequently but are mostly manageable without ICI discontinuation in patients with a preexisting autoimmune disease. Immunosuppressive therapy at baseline is associated with poorer outcomes.
- 2Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study
Annals of the rheumatic diseases · 2018
📚 232 citations🎯 RCR 8.43Top 3% NIH🩺 Clinique - 3EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Annals of the rheumatic diseases · 2021
Publications scientifiques (50) — classées par pathologie
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Transversal29
▼
Transversal29
▼- Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome
Blood · 2025 · Journal Article
Breillat P, Carbone F, Lereclus E, Riller Q, et al.
📚 5 cit.🎯 RCR 1.98 - Correction: Neurological manifestations in patients with VEXAS syndrome
Journal of neurology · 2025 · Published Erratum
Bert-Marcaz C, Fortanier É, Briantais A, Faucher B, et al.
- Neurological manifestations in patients with VEXAS syndrome
Journal of neurology · 2025 · Journal Article
Bert-Marcaz C, Fortanier É, Briantais A, Faucher B, et al.
📚 6 cit.🎯 RCR 2.42 - Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study
Joint bone spine · 2025 · Journal Article
Ladouceur A, Barnetche T, Prey S, Dutriaux C, et al.
📚 4 cit.🩺 Clinique - 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Annals of the rheumatic diseases · 2024 · Journal Article
Sebbag E, Lauper K, Molina-Collada J, Aletaha D, et al.
📚 21 cit.🎯 RCR 4.79🔬→🩺 Translationnel - Clinical impact of proton pump inhibitors and other co-medications on advanced melanoma patients treated with BRAF/MEK inhibitors
European journal of cancer (Oxford, England : 1990) · 2024 · Observational Study
Ramel E, Prey S, Dutriaux C, Gerard E, et al.
📚 3 cit.🩺 Clinique - Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
RMD open · 2023 · Observational Study
Ladouceur A, Barnetche T, Mouterde G, Tison A, et al.
📚 5 cit.🩺 Clinique - Clinical and immunological features of patients with cancer-associated systemic sclerosis: An observational study
Joint bone spine · 2023 · Observational Study
Lopez L, Barnetche T, Galli G, Seneschal J, et al.
📚 9 cit.🎯 RCR 1.70🩺 Clinique - Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases
Journal of the American Academy of Dermatology · 2023 · Multicenter Study
Zakine È, Papageorgiou L, Bourguiba R, Mekinian A, et al.
📚 51 cit.🎯 RCR 10.04🔬→🩺 Translationnel - Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Nature reviews. Rheumatology · 2022 · Journal Article
Tison A, Garaud S, Chiche L, Cornec D, et al.
📚 138 cit.🎯 RCR 8.98🔬→🩺 Translationnel - Short duration antibiotic therapy for native joint arthritis caused by Neisseria infection?
Annals of the rheumatic diseases · 2022 · Letter
Ducours M, El-Hout S, Desclaux A, Dutronc H, et al.
📚 4 cit. - Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
RMD open · 2022 · Observational Study
De La Fuente F, Belkhir R, Henry J, Nguyen CD, et al.
📚 13 cit.🎯 RCR 1.15🩺 Clinique - Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022 · Journal Article
Jensen AK, Chatzidionysiou K, Torp CK, Sørensen AS, et al.
📚 5 cit. - Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study
JAAD international · 2021 · Journal Article
Dousset L, Pacaud A, Barnetche T, Kostine M, et al.
📚 20 cit.🎯 RCR 1.08🔬→🩺 Translationnel - Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events
European journal of cancer (Oxford, England : 1990) · 2021 · Journal Article
Kostine M, Mauric E, Tison A, Barnetche T, et al.
📚 80 cit.🎯 RCR 4.14🔬→🩺 Translationnel - Mismatch repair deficiency is rare in bone and soft tissue tumors
Histopathology · 2021 · Case Reports
Lam SW, Kostine M, de Miranda NFCC, Schöffski P, et al.
📚 33 cit.🎯 RCR 1.93🔬→🩺 Translationnel - [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)]
Bulletin du cancer · 2021 · Journal Article
Tingry T, Massy E, Piperno M, Auroux M, et al.
📚 1 cit. - Rapidly progressive interstitial lung disease under FOLFOX treatment for colorectal cancer associated with systemic sclerosis: two case reports
Rheumatology (Oxford, England) · 2021 · Case Reports
El-Hout S, Lopez L, Schaeverbeke T, Richez C, et al.
📚 1 cit.🔬→🩺 Translationnel - EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Annals of the rheumatic diseases · 2021 · Consensus Statement
Kostine M, Finckh A, Bingham CO, Visser K, et al.
📚 196 cit.🎯 RCR 13.91🩺 Clinique - Multidisciplinary collaboration among young specialists: results of an international survey by the emerging EULAR network and other young organisations
RMD open · 2020 · Journal Article
Najm A, Kostine M, Pauling JD, Ferreira AC, et al.
📚 11 cit.🔬→🩺 Translationnel - Reply
Arthritis & rheumatology (Hoboken, N.J.) · 2020 · Letter
Tison A, Kostine M, Cornec D
- Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Journal for immunotherapy of cancer · 2019 · Journal Article
Manson G, Maria ATJ, Poizeau F, Danlos FX, et al.
📚 84 cit.🎯 RCR 3.64🔬→🩺 Translationnel - [Toxicities of immune checkpoint inhibitors and their management]
Medecine sciences : M/S · 2019 · Journal Article
Kostine M, Marabelle A, Schaeverbeke T, Kfoury M
📚 1 cit. - Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy
Rheumatology (Oxford, England) · 2019 · Journal Article
Kostine M, Truchetet ME, Schaeverbeke T
📚 35 cit.🎯 RCR 1.56🔬→🩺 Translationnel - EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases
RMD open · 2019 · Journal Article
Najm A, Nikiphorou E, Kostine M, Richez C, et al.
📚 76 cit.🎯 RCR 5.13🔬→🩺 Translationnel - Response to: 'Checkpoint inhibitors and arthritis: seeking balance between victories and defeats' by Moura and Moura
Annals of the rheumatic diseases · 2019 · Letter
Schaeverbeke T, Kostine M
📚 3 cit.🔬→🩺 Translationnel - Dark urine, hypotension and blood smear examination
Intensive care medicine · 2019 · Case Reports
Prevel R, Kostine M, Desclaux A, Souayed M
- Response to: 'Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor' by Chan and Bass
Annals of the rheumatic diseases · 2019 · Letter
Kostine M, Dousset L, Schaeverbeke T, FHU-ACRONIM
📚 1 cit. - Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?
Annals of the rheumatic diseases · 2019 · Letter
Kostine M, Cappelli LC, Calabrese C, Calabrese LH, et al.
📚 16 cit.🔬→🩺 Translationnel
Revue générale6
▼
Revue générale6
▼- Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: A narrative review
Joint bone spine · 2026 · Journal Article
Tison A, Escoda T, Kostine M, Cornec D, et al.
📚 1 cit. - Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Annals of the rheumatic diseases · 2025 · Journal Article
Sebbag E, Molina-Collada J, Ndoye R, Aletaha D, et al.
📚 10 cit.🎯 RCR 4.40🔬→🩺 Translationnel - The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review
Rheumatic diseases clinics of North America · 2024 · Journal Article
Ghosh N, Jivanelli B, Couette N, Singh N, et al.
📚 4 cit. - Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group
Seminars in arthritis and rheumatism · 2023 · Journal Article
Ghosh N, Couette N, van Binsbergen WH, Weinmann SC, et al.
📚 15 cit.🎯 RCR 1.76🔬→🩺 Translationnel - Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis
Joint bone spine · 2022 · Journal Article
Veccia A, Kostine M, Tison A, Dipasquale M, et al.
📚 6 cit.🔬→🩺 Translationnel - Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature
RMD open · 2019 · Case Reports
Calabrese C, Cappelli LC, Kostine M, Kirchner E, et al.
📚 61 cit.🎯 RCR 2.54🔬→🩺 Translationnel
Épidémiologie & registres5
▼
Épidémiologie & registres5
▼- Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry
Rheumatology (Oxford, England) · 2024 · Journal Article
Faganello D, Bertrand A, Meunier P, Avouac J, et al.
📚 2 cit. - Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry
Annals of the rheumatic diseases · 2024 · Multicenter Study
de Valence B, Delaune M, Nguyen Y, Jachiet V, et al.
📚 51 cit.🎯 RCR 10.11🔬→🩺 Translationnel - Diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease: Data from the French Tw-IRD registry
The Journal of infection · 2024 · Journal Article
Caillet Portillo D, Puéchal X, Masson M, Kostine M, et al.
📚 10 cit.🎯 RCR 3.31 - Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
Arthritis & rheumatology (Hoboken, N.J.) · 2019 · Evaluation Study
Tison A, Quéré G, Misery L, Funck-Brentano E, et al.
📚 245 cit.🎯 RCR 9.65🔬→🩺 Translationnel - Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study
Annals of the rheumatic diseases · 2018 · Journal Article
Kostine M, Rouxel L, Barnetche T, Veillon R, et al.
📚 232 cit.🎯 RCR 8.43🩺 Clinique
Revue / méta-analyse4
▼
Revue / méta-analyse4
▼- Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Annals of the rheumatic diseases · 2025 · Journal Article
Sebbag E, Molina-Collada J, Ndoye R, Aletaha D, et al.
📚 10 cit.🎯 RCR 4.40🔬→🩺 Translationnel - Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis
Joint bone spine · 2022 · Journal Article
Veccia A, Kostine M, Tison A, Dipasquale M, et al.
📚 6 cit.🔬→🩺 Translationnel - The response to TNF blockers depending on their comparator in rheumatoid arthritis clinical trials: the lessebo effect, a meta-analysis
Rheumatology (Oxford, England) · 2022 · Comparative Study
Lopez L, Griffier R, Barnetche T, Lhomme E, et al.
📚 4 cit.🔬→🩺 Translationnel - Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature
RMD open · 2019 · Case Reports
Calabrese C, Cappelli LC, Kostine M, Kirchner E, et al.
📚 61 cit.🎯 RCR 2.54🔬→🩺 Translationnel
Pharmacovigilance3
▼
Pharmacovigilance3
▼- Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis
Frontiers in oncology · 2024 · Journal Article
Eldani C, Kostine M, Faure M, Lazaro E, et al.
📚 13 cit.🎯 RCR 2.25 - Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study
European journal of cancer (Oxford, England : 1990) · 2022 · Clinical Trial, Phase IV
Panhaleux M, Espitia O, Terrier B, Manson G, et al.
📚 19 cit.🎯 RCR 1.43🩺 Clinique - Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
Arthritis & rheumatology (Hoboken, N.J.) · 2019 · Evaluation Study
Tison A, Quéré G, Misery L, Funck-Brentano E, et al.
📚 245 cit.🎯 RCR 9.65🔬→🩺 Translationnel
Case report / série2
▼
Case report / série2
▼- Case report: Parsonage-turner syndrome in a melanoma patient treated by BRAF/MEK inhibitors after immune checkpoint inhibitors
Frontiers in oncology · 2023 · Case Reports
Bonnefin C, Duval F, Rouanet M, Kostine M, et al.
- Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature
RMD open · 2019 · Case Reports
Calabrese C, Cappelli LC, Kostine M, Kirchner E, et al.
📚 61 cit.🎯 RCR 2.54🔬→🩺 Translationnel
Corticothérapie1
▼
Corticothérapie1
▼- Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial
European journal of cancer (Oxford, England : 1990) · 2025 · Journal Article
Roubaud G, Kostine M, McDermott RS, Bernard-Tessier A, et al.
📚 5 cit.🎯 RCR 1.65🩺 Clinique
Essai clinique1
▼
Essai clinique1
▼- Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study
European journal of cancer (Oxford, England : 1990) · 2022 · Clinical Trial, Phase IV
Panhaleux M, Espitia O, Terrier B, Manson G, et al.
📚 19 cit.🎯 RCR 1.43🩺 Clinique
Fièvres auto-inflammatoires1
▼
Fièvres auto-inflammatoires1
▼- Pleuropulmonary Manifestations of Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome
Chest · 2023 · Journal Article
Borie R, Debray MP, Guedon AF, Mekinian A, et al.
📚 46 cit.🎯 RCR 6.18
IA en rhumatologie1
▼
IA en rhumatologie1
▼- Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas
PLoS computational biology · 2019 · Journal Article
van IJzendoorn DGP, Szuhai K, Briaire-de Bruijn IH, Kostine M, et al.
📚 57 cit.🎯 RCR 2.51
Lupus1
▼
Lupus1
▼- Response to: 'Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1' by Michot et al and 'Checkpoint inhibitor-associated immune arthritis' by Arnaud et al
Annals of the rheumatic diseases · 2019 · Letter
Kostine M, Richez C, Schaeverbeke T, FHU- ACRONIM
📚 3 cit.
Sjögren1
▼
Sjögren1
▼- Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)
Clinical and experimental rheumatology · 2019 · Journal Article
Ramos-Casals M, Maria A, Suárez-Almazor ME, Lambotte O, et al.
📚 78 cit.🎯 RCR 3.24🔬→🩺 Translationnel
Vascularites1
▼
Vascularites1
▼- Response to: 'Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors' by Delyon et al
Annals of the rheumatic diseases · 2019 · Letter
Kostine M, Schaeverbeke T, FHU-ACRONIM
📚 5 cit.🔬→🩺 Translationnel
Datasets & protocoles partagés
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Collection2019figshareAbstract Background Paraneoplastic syndromes (PNS) are autoimmune disorders specifically associated with cancer. There are few data on anti-PD-1 or anti-PD-L1 immunotherapy in patients with a PNS. Our objective was to de
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Collection2015FigshareAbstract Background Targeting CTLA-4 is a recent strategic approach in cancer control: blocking CTLA-4 enhances an antitumor immunity by promoting T-cell activation and cytotoxic T-lymphocyte proliferation. This inductio
High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas
Collection2016FigshareAbstract Background Previous studies on high grade sarcomas using mass spectrometry imaging showed proteasome activator complex subunit 1 (PSME1) to be associated with poor survival in soft tissue sarcoma patients. PSME1
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Collection2015FigshareAbstract Background Targeting CTLA-4 is a recent strategic approach in cancer control: blocking CTLA-4 enhances an antitumor immunity by promoting T-cell activation and cytotoxic T-lymphocyte proliferation. This inductio
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Collection2019figshareAbstract Background Paraneoplastic syndromes (PNS) are autoimmune disorders specifically associated with cancer. There are few data on anti-PD-1 or anti-PD-L1 immunotherapy in patients with a PNS. Our objective was to de
High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas
Collection2016FigshareAbstract Background Previous studies on high grade sarcomas using mass spectrometry imaging showed proteasome activator complex subunit 1 (PSME1) to be associated with poor survival in soft tissue sarcoma patients. PSME1
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).